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Over the past few years, various technologies have been developed to enable a partially or fully integrated 
continuous bioprocessing platform. Many companies have explored the potentials of these innovative production 
systems and a lot of data has been published that support the technical viability of integrated continuous 
bioprocessing. 
 
The regulatory agencies, such as the FDA, have repeatedly expressed their support for these developments as 
they recognize the potentials for enhanced process and product quality control. In addition to this, continuous 
bioprocessing may allow the industry to move towards a more agile state that would allow biopharmaceutical 
products to become available to a wider audience at lower costs. 
 
Even though the regulators are supportive, no guidance was provided in terms of the regulators’ for submissions 
and how the guidelines as summarized in ICH Q8 and Q9 can be applied in continuous bioprocessing. 
 
Many different companies working towards integrated continuous bioprocessing platforms, all of which are 
relying on a combination of innovative and existing technologies. In order to facilitate and harmonize the 
interactions with the regulatory bodies, we have developed strategies and approaches that would cover the 
typical regulatory aspects of integrated continuous manufacturing platforms, covering both upstream and 
downstream processing. 
 
In this presentation, we will present and discuss regulatory strategies for integrated continuous bioprocessing. 
This will cover critical quality attributes, bioburden control and virus safety strategies for continuous 
bioprocessing platforms. In addition to this, some aspects of traceability, lot definitions and deviation 
management will be addressed. 
